We have initiated a clinical trial to assess the efficacy and safety of a drug that inhibits the proteases of a bacterium (P.gingivalis) that is detected in the brains of Alzheimer’s patients. It is a new approach to this pathology, absolutely different from the rest of ongoing projects. More information at www.gaintrial.com.
